Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Bionomics Finishes Twin BNC210 Trials

March 30, 2011 7:00 am | News | Comments

Bionomics Limited has successfully concluded two Phase 1b clinical trials of BNC210 which is being developed as a new generation treatment for anxiety and depression.

TOPICS:

Nycomed Launching New Daxas Trial

March 30, 2011 6:55 am | News | Comments

Nycomed announced plans for a phase 3/4 study investigating the effect of Daxas versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists and inhaled corticosteroids.

TOPICS:

Curacyte Drug Trial Sees Positive Results at Midpoint

March 30, 2011 6:51 am | News | Comments

The PHOENIX trial is a placebo-controlled Phase 3 study treating catecholamine-resistant patients in distributive shock with the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene conjugate.

TOPICS:
Advertisement

GSK-Valeant Drug Granted EU Marketing Rights

March 30, 2011 6:47 am | News | Comments

GlaxoSmithKline PLC says its seizure drug developed with Valeant Pharmaceuticals Inc. has been granted marketing authorization by the European Union. Trobalt is intended to treat partial onset seizures in adults with epilepsy.

TOPICS:

3D Tissue Modeling

March 29, 2011 8:39 am | Product Releases | Comments

TAP Biosystems, a supplier of innovative automation and consumables for life science applications, announced it is introducing a 96-well version of its RAFT system for the generation of consistent multi-cellular 3D tissue models.

TOPICS:

Cell Analyzer

March 29, 2011 8:36 am | Drug Discovery & Development | Product Releases | Comments

GE Healthcare’s IN Cell Analyzer 6000 is a laser-based, confocal imaging platform designed for demanding high-content cellular assays and screens including live cell assays, 3D imaging, co-localization studies and imaging of assays with low signal.

TOPICS:

Particles Can Change Colors to Tag Molecules

March 29, 2011 8:29 am | News | Comments

Engineers have invented a new kind of nano-particle that shines in different colors to tag molecules in biomedical tests. These tiny plastic nano-particles are stuffed with even tinier bits of electronics called quantum dots.

TOPICS:

Stapled Peptides Show Promise Against Cancer, Asthma

March 29, 2011 8:25 am | News | Comments

In what they described as the opening of a new era in the development of potentially life-saving new drugs, scientists reported discovery of a way to tone down an overactive gene involved in colon cancer and block a key protein involved in asthma attacks.

TOPICS:
Advertisement

Millipore Launches Profiling Service

March 29, 2011 8:22 am | News | Comments

EMD Millipore launched its new SignalProfiler Services. Researchers can use these new services to profile the safety and efficacy of potential drug compounds against multiple signaling pathways using their choice of cell types.

TOPICS:

INC Releases New White Paper

March 29, 2011 8:19 am | News | Comments

INC Research, LLC announced it has released a new white paper entitled, “Win with Networked Drug Development Alliances: New Strategies to Increase Productivity and Mitigate Risk.”

TOPICS:

FDA Approves Zyclara Cream

March 29, 2011 8:16 am | News | Comments

Graceway Pharmaceuticals announced that the Food and Drug Administration has approved Zyclara Cream for the treatment of external genital and perianal warts in patients 12 years of age and older.

TOPICS:

Genentech Says Lucentis Met Goal in Second Trial

March 29, 2011 8:14 am | News | Comments

Genentech announced that the second of two Phase 3 trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint. The primary endpoint was the ability to read at least 15 additional letters on an eye chart.

TOPICS:

Omega-3 Free Fatty Acid for Treatment of Hypertriglyceridemia and Mixed Dyslipidemia

March 29, 2011 8:04 am | by Jerry Wisler, President and Chief Executive Officer; Omthera Pharmaceuticals, Bedminster, NJ | Articles | Comments

Severe hypertriglyceridemia, or very high triglycerides (?500 mg/dL), is a serious and growing lipid disorder that currently impacts more than five million Americans and is associated with an increased risk of pancreatitis and heart disease.

TOPICS:

Drug Repositioning: A Union of Patient Interests, Pipeline Development and Innovation

March 29, 2011 7:59 am | by Aris Persidis, PhD, President; Biovista, Inc., Charlottesville, Va. | Articles | Comments

The tremendous pressures on pharmaceutical company pipelines are always in the news. Constant reorganizations and acquisitions of late-stage clinical candidates or of entire companies are seen as a major solution going forward.

New Insight into How 'Tidying Up' Enzymes Work

March 29, 2011 7:53 am | News | Comments

When a tablet of medicine is taken, the active molecules get absorbed into the bloodstream through the gut and make their way around the body, including to the cells in which they are intended to act; however, it's important they don't stay in the body forever.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading